Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Rhea-AI Summary
Tango Therapeutics (NASDAQ: TNGX) announced that Adam Crystal, M.D., Ph.D., President of Research & Development, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 1:30pm ET.
The event will be live webcast via the company's Investors > Events & Presentations page on the day of the presentation, and a replay will be archived on the company's website for 90 days following the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – TNGX
In the Nov 26 session, TNGX gained 1.80%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 26 | Conference participation | Neutral | +1.8% | Announced Piper Sandler healthcare conference fireside chat and webcast details. |
| Nov 12 | Conference participation | Neutral | -8.5% | Jefferies Global Healthcare Conference fireside chat and webcast information. |
| Nov 04 | Earnings and pipeline | Positive | +0.0% | Profitable Q3 2025, strong cash and positive vopimetostat clinical data. |
| Oct 29 | Earnings notice | Neutral | +0.5% | Scheduled Q3 2025 results release with no accompanying conference call. |
| Oct 23 | Equity financing | Negative | -13.1% | Underwritten offering and PIPE totaling about $225M in gross proceeds. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Conference participation headlines have produced modest, mixed reactions, while financing news coincided with a sharper decline and earnings-related fundamentals had a flat price response.
Over the last few months, Tango reported multiple corporate and financing milestones. An October $225 million financing with common stock and pre-funded warrants was followed by Q3 2025 results showing $15.9M net income and a strengthened cash position. Subsequent filings detailed additional liquidity actions and clinical updates. Conference participation announcements, including Jefferies and Piper Sandler events, generated relatively small but mixed price moves. Against this backdrop, the latest Piper Sandler conference participation fits into a pattern of ongoing investor outreach rather than a new fundamental inflection point.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is scheduled to participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 1:30pm ET.
The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.
Investors and Media:
Elizabeth Hickin
IR@tangotx.com
media@tangotx.com
